Geisinger Health System’s Neuroscience Institute of Danville, Pa., is using optical molecular imaging technology from Carestream Molecular Imaging as part of its research of brain cancer treatment.
The company said that the objective of the research is to make surgery for brain tumors and inflammatory lesions simpler and more precise by using fluorescent nanospheres to easily visualize tumors and lesions during treatment procedures.
Carestream said Geisinger’s neuroscience lab chose its Kodak In-Vivo Multispectral Imaging System FX to assess which nanoparticles would be efficacious for image-guided brain surgery in patients in the future.
Steven A. Toms, MD, Geisinger’s director of neurosurgery and co-director of the Neuroscience Institute, is leading the research.
The Kodak In-Vivo Multispectral Imaging System FX is designed to locate and monitor changes in molecular activity of specific cells or organs, such as the brain—before morphological changes can be detected—aiding the development of therapeutics for disease treatment, Carestream said. The system’s multispectral tuning of excitation light enhances image sensitivity, allowing for the identification and separation of multiple optical biological marker signals in subjects such as small animals, while removing background noise, according to the company.